Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Phase 1/2 preliminary results of NKTR-214 (PEG-rhuIL-2) in combination with nivolumab in advanced solud tumors (PIVOT trial)

Source Link:: http://iplanner.asco.org/am2018/

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

BMY

100%

NKTR

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Clinical Data Abstract 3006NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT.

http://iplanner.asco...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Jun 02, 2018

Occurred Source:

http://ir.nektar.com/news-releases/news-release-details/preliminary-data-nktr-214-combination-opdivo-nivolumab-patients

Related Projects

Discussing the NSCLC landscape after KEYNOTE-189 data, specifically PD-1 combo programs MRK, ARMO, NKTR Executed On: Apr 30, 2018 at 10:00 AM EDT

Related Keywords Il-2, Nktr-214, Interleukin, Cytokine, Cancer Immunotherapy, Opdivo, Checkpoint Inhibitor, Pd-1 Checkpoint Inhibitor